Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.53 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.53 |
| ▸ | ITGAL | P20701 | 4/20 | 0.53 |
| ▸ | NMBR | P28336 | 2/20 | 0.52 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850319 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL29350138 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL29350130 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL119594 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL119372 | 1.00 | ALOX15 (0.56) | ALOX15ACEFPR2ITGB2ICAM1 | |
| Water SCHEMBL6022940 | 0.99 | ALOX15 (0.55) | ALOX15ACEFPR2ITGB2ICAM1 | |
| Fluoride SCHEMBL7154596 | 0.99 | ALOX15 (0.55) | ALOX15ACEFPR2ITGB2ICAM1 | |
| SCHEMBL29903356 | 0.93 | NMBR (0.55) | ACENMBRECE1 | |
| SCHEMBL30310986 | 0.93 | ACE (0.53) | ACEECE1 | |
| SCHEMBL29903302 | 0.93 | NMBR (0.55) | ACENMBRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211130-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | COMPASS Pathfinder Limited (GB) | 2023-07-19 | — | — | EP | claimed |
| CN-116075499-A | Novel dephosphorylated galectin derivatives with prodrug properties | 指南针探路者有限公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2022053696-A1 | NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES | COMPASS PATHFINDER LIMITED (GB) | 2022-03-17 | — | — | WO | claimed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| CN-111655758-B | Nucleic acid delivery polymers | 国立大学法人东京大学 | 2024-03-22 | — | — | CN | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116640182-A | Transdermal delivery system for polypeptides and related compounds | 泰飞尔生物医药(苏州)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116075499-A | Novel dephosphorylated galectin derivatives with prodrug properties | 指南针探路者有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ALOX15 3621/4885ACE 621/4885FPR2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.